Clinical Profile and Risk Factors of Central Serous Chorioretinopathy in Al-
Ain, United Arab Emirates

Manish      Jain; Dhanya      Kurian; Sarath      Lal; Jyotirmay      Biswas; Komal      Pathak

doi:10.2174/03666220428133215

Abstract

Background: Based on the adverse event reporting system, the authors observed unique occupational and pharmacological trends in central serous chorioretinopathy (CSC); despite being a common condition in the region, there are no large epidemiological studies.

Objective: The study aims to describe the clinical profile, risk factors, and co-medications of CSC in a multispecialty hospital in the UAE.

Methods: Hospital based retrospective, observational study in which all the confirmed cases of CSC (272) seen between 2010 and 2019 were included. Supplementary data were collected on follow up visits or through telephonic calls.

Results:The male: female ratio was 17:1; low socio-economic status was (155; 73.45%), and occupations such as drivers (61; 28.9%) and outdoor laborers (59; 27.96%) were the most commonly affected. The majority (78.05%; 185) were single expatriates. Financial worries (105; 50.72%) constituted the leading cause of stress. The usage of corticosteroids (83; 30.51%), nasal decongestants (14.70%), or both (17; 6.25%) within one year was common; mostly (82; 30.14%) for rhinitis/respiratory states, though grossly under-recognized. Muscle relaxants and psychotropic medications were the other major medications used in 24 (8.82%) and 25 (9.19%) cases prior to CSC. Seven of 15 women had at least one condition that alters the endocrinal milieu: Pregnancy (3), recent child birth (1), erratic oral contraceptive intake (1), menopause with liver dysfunction (1), hormone replacement therapy for menopause and endometriosis (1), ovarian cyst and infertility (1) hypothyroidism (3), and cushing syndrome (1). Chronic/ recurrent forms were seen in 31.08%. There were too few glaucoma patients despite both CSC and glaucoma being common among our patients.

Conclusion: CSC in Al-Ain predominantly affected males with a specific occupational predisposition. Emotional distress, financial worries, allergic disorders, and endocrinal disorders (among females) were common. Adverse drug events were under-reported compared to the usage of steroid or decongestant users. Suspected pharmacological associations included drugs that modulated the vasomotor tone.

Keywords: Central serous chorioretinopathy, Co-medications, Epidemiology, Nasal decongestants, Psychotropic drugs, Risk factors.

[1]
von Graefe A. Über zentrale rezidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol  1866; 12: 211-5.

[2]
Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol  1999; 128(1): 63-8.
 [http://dx.doi.org/10.1016/S0002-9394(99)00075-6] [PMID: 10482095]

[3]
Liu B, Deng T, Zhang J. Risk factors for central serous chorioretinopathy: A systematic review and metaanalysis. Retina  2016; 36(1): 9-19.
 [http://dx.doi.org/10.1097/IAE.0000000000000837] [PMID: 26710181]

[4]
Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M. Patient characteristics and risk factors for central serous chorioretinopathy: An analysis of 811 patients. Br J Ophthalmol  2019; 103(6): 725-9.
 [http://dx.doi.org/10.1136/bjophthalmol-2018-312431] [PMID: 30002072]

[5]
Matet A, Daruich A, Behar-Cohen F. Risk factors inCentral Serous Chorioretinopathy.Academic Press.   2019; pp. 35-47.

[6]
Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology  2002; 109(10): 1834-7.
 [http://dx.doi.org/10.1016/S0161-6420(02)01117-X] [PMID: 12359603]

[7]
Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol  2003; 136(1): 182-5.
 [http://dx.doi.org/10.1016/S0002-9394(03)00076-X] [PMID: 12834690]

[8]
Said-Ahmed K, Moustafa G, Fawzy M. Incidence and natural course of symptomatic central serous chorioretinopathy in pregnant women in a maternity hospital in Kuwait. Middle East Afr J Ophthalmol  2012; 19(3): 273-6.
 [http://dx.doi.org/10.4103/0974-9233.97920] [PMID: 22837618]

[9]
Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest  2012; 122(7): 2672-9.
 [http://dx.doi.org/10.1172/JCI61427] [PMID: 22684104]

[10]
Jain M. Quetiapine associated Central Serous Chorioretinopathy: Implicit role of serotonin and dopamine pathways. Indian J Ophthalmol  2019; 67(2): 292-4.
 [http://dx.doi.org/10.4103/ijo.IJO_929_18] [PMID: 30672500]

[11]
Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J  2013; 13(4): 533-40.
 [PMID: 24358002]

[12]
Gungor Kobat S, Yusufoglu E, Gul FC, Keser S, Kalayci M. Plasma dopamine and catecholamine levels in patients with central serous chorioretinopathy. J Fr Ophtalmol  2021; 44(5): 621-5.
 [http://dx.doi.org/10.1016/j.jfo.2020.08.032] [PMID: 33865632]

[13]
Bujarborua D, Borooah S, Dhillon B. Getting serious with retinopathy: Approaching an integrated hypothesis for central serous chorioretinopathy. Med Hypotheses  2013; 81(2): 268-73.
 [http://dx.doi.org/10.1016/j.mehy.2013.04.032] [PMID: 23669373]

[14]
Kimura T, Araki T, Komuku Y, Iwami H, Gomi F. Central serous chorioretinopathy and blood serotonin concentrations. J Clin Med  2021; 10(4): 558.
 [http://dx.doi.org/10.3390/jcm10040558] [PMID: 33546112]

[15]

http://worldpopulationreview.com/countries/united-arab-emirates-population/

[16]
Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol  2008; 86(2): 126-45.
 [http://dx.doi.org/10.1111/j.1600-0420.2007.00889.x] [PMID: 17662099]

[17]
Scarinci F, Mezzana P, Pasquini P, Colletti M, Cacciamani A. Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness. Cutan Ocul Toxicol  2012; 31(2): 157-9.
 [http://dx.doi.org/10.3109/15569527.2011.613427] [PMID: 21939432]

[18]
Nuzzi R, Scalabrin S, Becco A, Panzica G. Gonadal hormones and retinal disorders: A review. Front Endocrinol (Lausanne)  2018; 9: 66.
 [http://dx.doi.org/10.3389/fendo.2018.00066] [PMID: 29551993]

[19]
da Cruz NFS, Polizelli MU, Cezar LM, et al. Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: A literature review. Int J Retina Vitreous  2020; 6(38)

[20]
Gordon-Bennett P, Rimmer T. Central serous chorioretinopathy following oral tadalafil. Eye (Lond)  2012; 26(1): 168-9.
 [http://dx.doi.org/10.1038/eye.2011.250] [PMID: 22056864]

[21]
Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: A case-control study. Invest Ophthalmol Vis Sci  2006; 47(8): 3474-8.
 [http://dx.doi.org/10.1167/iovs.05-1246] [PMID: 16877418]

[22]
Artunay O, Senel A, Sengul A, Rasier R, Bahcecioglu H. Central serous chorioretinopathy associated with topical latanoprost therapy. Ocul Immunol Inflamm  2011; 19(6): 453-5.
 [http://dx.doi.org/10.3109/09273948.2011.619680] [PMID: 22106918]

[23]
Ayhan Tuzcu E, Keskin U, Coskun M, Ilhan O, Daglıoglu M, Oksuz H. Bilateral serous detachment associated with latanoprost/timolol fixed combination use: A report of one phakic case. Case Rep Ophthalmol Med  2012; 2012305379
 [http://dx.doi.org/10.1155/2012/305379] [PMID: 23304588]

[24]
Jain M, Nevin RL, Ahmed I. Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: A case report. J Med Case Reports  2016; 10(1): 305.
 [http://dx.doi.org/10.1186/s13256-016-1091-4] [PMID: 27799060]

[25]
Imamura Y, Fujiwara T, Spaide RF. Frequency of glaucoma in central serous chorioretinopathy: A case-control study. Retina  2010; 30(2): 267-70.
 [http://dx.doi.org/10.1097/IAE.0b013e3181c2e0f4] [PMID: 19996820]

[26]
Tsai DC, Chen SJ, Huang CC, et al. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: A population-based study in Taiwan. Retina  2014; 34(9): 1867-74.
 [http://dx.doi.org/10.1097/IAE.0000000000000159] [PMID: 24743638]

[27]
Sahoo NK, Singh SR, Kammari P, Jonnadula GB, Das AV, Chhablani J. Prevalence and Profile of Central Serous Chorioretinopathy in an Indian Cohort. Nepal J Ophthalmol  2019; 11(21): 5-10.
 [http://dx.doi.org/10.3126/nepjoph.v11i1.25410] [PMID: 31523060]

[28]
Reynolds ME, Karesh JW, Oh GT, Stahlman S. Incident and recurrent cases of central serous chorioretinopathy, active component, U.S. Armed Forces, 2001-2018. MSMR  2019; 26(9): 31-4.
 [PMID: 31557049]

[29]
Jamil AZ, Mirza KA, Qazi ZU, et al. Features of central serous chorioretinopathy presenting at a tertiary care hospital in Lahore. J Pak Med Assoc  2013; 63(4): 478-82.
 [PMID: 23905445]

[30]
Rouvas AA, Chatziralli IP, Ladas ID, et al. The impact of financial crisis on central serous chorioretinopathy in Greece: Is there any correlation? Eur J Ophthalmol  2014; 24(4): 559-65.
 [http://dx.doi.org/10.5301/ejo.5000403] [PMID: 24338576]

[31]
Lajmi H, Hmaied W, Ben Jalel W, Akremi A, El Fekih L. Central serous chorioretinopathy: Professional repercussions among agents of the internal security forces. J Fr Ophtalmol  2018; 41(8): 739-43.
 [http://dx.doi.org/10.1016/j.jfo.2017.12.012] [PMID: 30217609]

[32]
Islam QU, Hanif MK, Tareen S. Frequency of systemic risk factors in Central Serous Chorioretinopathy. J Coll Physicians Surg Pak  2016; 26(8): 692-5.
 [PMID: 27539765]

[33]
Bousquet E, Dhundass M, Lehmann M, et al. Shift work: A risk factor for Central Serous Chorioretinopathy. Am J Ophthalmol  2016; 165: 23-8.
 [http://dx.doi.org/10.1016/j.ajo.2016.02.012] [PMID: 26915576]

[34]
Setrouk E, Hubault B, Vankemmel F, et al. Circadian disturbance and idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol  2016; 254(11): 2175-81.
 [http://dx.doi.org/10.1007/s00417-016-3378-y] [PMID: 27207466]

[35]
Penas S, Castro P, Pereira G, et al. Cerebral neurovascular coupling impairment in central serous chorioretinopathy. Ophthalmic Res 2020. Epub ahead of print
 [http://dx.doi.org/10.1159/000509553] [PMID: 32564029]

[36]
Majumder PD, Menia N, Sudharshan S, Rao C, Ganesh SK, Biswas J. Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India. Indian J Ophthalmol  2019; 67(2): 247-51.
 [http://dx.doi.org/10.4103/ijo.IJO_831_18] [PMID: 30672479]

[37]
Kido A, Miyake M, Tamura H, et al. Incidence of central serous chorioretinopathy (2011-2018): A nationwide population-based cohort study of Japan. Br J Ophthalmol 2021. Epub ahead of print
 [http://dx.doi.org/10.1136/bjophthalmol-2021-319403]

[38]
Birchall W, Charles SJ, Buckler HM. Cyclical central serous chorloretinopathy associated with cystoid macular oedema. Br J Ophthalmol  2001; 85(6): 756-8.
 [http://dx.doi.org/10.1136/bjo.85.6.754-d] [PMID: 11426426]

[39]
Valenzuela RM, Rai R, Kirk BH, et al. An estimation of the risk of Pseudotumor Cerebri among users of the levonorgestrel intrauterine device. Neuroophthalmology  2017; 41(4): 192-7.
 [http://dx.doi.org/10.1080/01658107.2017.1304425] [PMID: 29344058]

[40]
van Dijk EHC, de Roon Hertoge KL, Boon CJF. Central serous chorioretinopathy. Central serous chorioretinopathy in a myopic patient with pachychoroid. Ophthalmology@point of care  2017; 1(1)
 [http://dx.doi.org/10.5301/oapoc.0000007]

[41]
Mazumdar S, Tripathy K, Sarma B, Agarwal N. Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake. Eur J Ophthalmol  2019; 29(1): NP21-4.
 [http://dx.doi.org/10.1177/1120672118797286] [PMID: 30175623]

[42]
Muñoz Morales A, Sánchez-Vicente JL, Franco Ruedas C, de Las Morenas Iglesias J, Espiñeira Periñán MÁ, López-Herrero F. Macular neurosensory retinal detachment associated with topiramate use. Arch Soc Esp Oftalmol  2019; 94(12): 614-8.
 [http://dx.doi.org/10.1016/j.oftale.2019.07.014] [PMID: 31610900]

[43]
Yoshioka H, Katsume Y, Akune H. Experimental central serous chorioretinopathy in monkey eyes: Fluorescein angiographic findings. Ophthalmologica  1982; 185(3): 168-78.
 [http://dx.doi.org/10.1159/000309239] [PMID: 7133631]